Arcturus Therapeutics Holdings Inc.
General ticker "ARCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $253.6M (TTM average)
Arcturus Therapeutics Holdings Inc. follows the US Stock Market performance with the rate: 0.1%.
Estimated limits based on current volatility of 4.5%: low 13.99$, high 15.32$
Factors to consider:
- Total employees count: 111 (-36.9%) as of 2025
- Top business risk factors: Significant losses, Need additional capital, CSL seqirus dependency, Clinical trial failure, Regulatory and compliance
- Current price 48.6% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.19$, 10.66$]
- 2026-12-31 to 2027-12-31 estimated range: [4.35$, 10.59$]
Financial Metrics affecting the ARCT estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: 69.38 < Shareholder equity ratio, % of 78.92 <= 81.92
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 3.45 <= 4.02
Short-term ARCT quotes
Long-term ARCT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $166.80MM | $152.31MM | $82.03MM |
| Operating Expenses | $245.00MM | $247.98MM | $158.29MM |
| Operating Income | $-78.20MM | $-95.67MM | $-76.26MM |
| Non-Operating Income | $50.31MM | $14.72MM | $10.48MM |
| Interest Expense | $0.77MM | $0.00MM | $0.00MM |
| R&D Expense | $192.13MM | $195.16MM | $112.21MM |
| Income(Loss) | $-27.89MM | $-80.94MM | $-65.78MM |
| Taxes | $1.83MM | $-0.00MM | $0.00MM |
| Net Income(Loss)* | $-29.73MM | $-80.94MM | $-65.78MM |
| Stockholders Equity | $278.51MM | $240.98MM | $213.99MM |
| Assets | $429.40MM | $344.07MM | $271.15MM |
| Operating Cash Flow | $-18.10MM | $-59.75MM | $-74.27MM |
| Capital expenditure | $2.90MM | $0.65MM | $0.23MM |
| Investing Cash Flow | $-2.90MM | $-0.65MM | $-0.23MM |
| Financing Cash Flow | $-24.09MM | $5.42MM | $13.38MM |
| Earnings Per Share** | $-1.12 | $-3.00 | $-2.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.